Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/134676
Title: ROLE OF CD137 SIGNALING IN IMMUNE DEVIATION OF HODGKIN LYMPHOMA AND ITS UTILISATION IN DEVELOPMENT OF IMMUNOTHERAPY
Authors: SAKTHI RAJENDRAN
Keywords: Hodgkin lymphoma, CD137, IL-13,immune deviation, EBV, LMP1
Issue Date: 17-Aug-2016
Citation: SAKTHI RAJENDRAN (2016-08-17). ROLE OF CD137 SIGNALING IN IMMUNE DEVIATION OF HODGKIN LYMPHOMA AND ITS UTILISATION IN DEVELOPMENT OF IMMUNOTHERAPY. ScholarBank@NUS Repository.
Abstract: CD137, a member of the tumor necrosis factor receptor (TNFR) superfamily has been reported to be ectopically expressed on Hodgkin and Reed-Sternberg (HRS) cells, the malignant cells in Hodgkin lymphoma (HL). Here we report that, CD137 signaling in HRS cells induces the secretion of IL-13, a Th2 cytokine. IL-13 in conditioned supernatants from CD137-stimulated HRS cell lines inhibits the secretion of an essential Th1 cytokine, IFN-in peripheral blood mononuclear cells. Hence, CD137-induced IL-13 secretion facilitates escape of HRS cells from immune surveillance, through downregulation of IFN-Γ. Targeting CD137 can be a potential therapeutic option for HL patients. Bi-specific antibodies against CD137 and CD30 were generated and tested for their ability to preferentially lyse CD30+CD137+ HRS cells in vitro. To summarize, this study has identified CD137 signaling as a mechanism of immune deviation in HL, and evaluated the efficacy of bi-specific antibodies against CD30 and CD137 as a potential immunotherapy for HL.
URI: http://scholarbank.nus.edu.sg/handle/10635/134676
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Sakthi_electronic thesis.pdf4.5 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

56
checked on Apr 19, 2019

Download(s)

18
checked on Apr 19, 2019

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.